(76) collected 246 patient’s sera from patients diagnosed with breast cancer for the first time for a cohort study and found that disease-free and overall survival rates were greater in patients with estrogen or progesterone receptor positive tumor cells who had detectable levels of sLAG-3 at diagnosis versus patients with undetectable sLAG-3 levels. This evidence concerns the gene LAG3 and breast carcinoma.